CoChat

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

Open access

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

PURPOSE: To elucidate the mechanism by which trastuzumab, a humanized monoclonal antibody against HER2 with proven survival benefit in women with HER2-positive metastatic breast cancer, mediates its antitumor activity. EXPERIMENTAL DESIGN: A pilot study including 11 patients with HER2-positive tumors treated in a neo-adjuvant setting with trastuzumab was performed. Trastuzumab was administered i.v. at a dose of 4 mg/kg followed by three weekly i.v. doses of 2 mg/kg. The primary tumor was surgically removed 7 days after the last treatment. Surgical samples, tumor biopsies, and lymphocytes from these patients were collected for biological studies. RESULT: Clinical data indicated one complete pathological remission and four partial remissions using RECIST (Response Evaluation Criteria in Solid Tumors). Trastuzumab was well tolerated and neither serious adverse events nor changes in cardiac function were observed during this short-term treatment and after surgery. The biological data showed that, independent of response, (a) all patients showed high levels of circulating trastuzumab; (b) saturating level of trastuzumab was present in all of the tumors; (c) no down-modulation of HER2 was observed in any tumors; (d) no changes in vessel diameter was observed in any tumors; (e) no changes in proliferation was observed in any tumors; and (f) a strong infiltration by lymphoid cells was observed in all cases. Patients with complete remission or partial remission were found to have a higher in situ infiltration of leukocytes and a higher capability to mediate in vitro antibody-dependent cellular cytotoxicity activity. CONCLUSIONS: The results of this pilot study argue against trastuzumab activity in patients through down-modulation of HER2 but in favor of antibody-dependent cellular cytotoxicity guiding efforts to optimize the use of trastuzumab in breast cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-0225

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 516

Metadata

Authors
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., Oliviero, B., Ballardini, B., Prada, G. D., Zambelli, A., & Costa, A.
Affiliations
  • European Institute of Oncology (IT)
  • 2Department of Experimental Oncology, Molecular Targeting Unit, Istituto Nazionale Tumori, Milano, Italy;
  • Fondazione Salvatore Maugeri (IT)
  • 4Division of Medical Oncology and
  • Istituti Clinici Scientifici Maugeri (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Policlinico San Matteo Fondazione (IT)
  • MultiMedica (IT)
Venue
Clinical Cancer Research
Published
2004-09-01
Volume
10
Issue
17
Pages
5650-5655
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2107426197
Cited by
516
References
13
Citations by year
2026: 4 · 2025: 8 · 2024: 16 · 2023: 20 · 2022: 18 · 2021: 17 · 2020: 16 · 2019: 22 · 2018: 20 · 2017: 16 · 2016: 22 · 2015: 26 · 2014: 24 · 2013: 24 · 2012: 31
FWCI
11.83
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
Funders
American-Italian Cancer Foundation
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
trastuzumab, HER2-positive breast cancer, mechanism of action, neoadjuvant therapy, antibody-dependent cellular cytotoxicity, lymphocyte infiltration, tumor vascularization, tumor cell proliferation, pathological complete response
MeSH terms
Trastuzumab, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Lymphocytes, Pilot Projects, Preoperative Care, Remission Induction, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy, Cell Proliferation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0225
The paper
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., Oliviero, B., Ballardini, B., Prada, G. D., Zambelli, A., & Costa, A. (2004). Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.